Winston Kung - Sep 21, 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ Maria Dobek, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Sep 21, 2022
Transactions value $
$0
Form type
4
Date filed
9/22/2022, 06:00 PM
Previous filing
Apr 21, 2022
Next filing
Jan 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +30K $0.00 30K Sep 21, 2022 Common Stock 30K $13.54 Direct F1
transaction JANX Stock Option (right to buy) Award $0 +9.38K $0.00 9.38K Sep 21, 2022 Common Stock 9.38K $13.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest in equal monthly installments over a three year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date.
F2 The shares subject to the option vest in equal monthly installments over a one year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the first anniversary of the Grant Date.